Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
CRISPR Therapeutics AG (CRSP) had Return on Investments of -5.59% for the most recently reported fiscal quarter, ending 2024-03-31.
| Income Statement Financials | |
$0.50M |
|
$-116.59M |
|
-- |
|
$0.50M |
|
$141.09M |
|
$-140.59M |
|
$24.72M |
|
$-115.87M |
|
$-115.87M |
|
$-116.59M |
|
$-116.59M |
|
$-116.59M |
|
$-116.59M |
|
$-140.59M |
|
$-135.75M |
|
81.79M |
|
81.79M |
|
$-1.43 |
|
$-1.43 |
|
| Balance Sheet Financials | |
$2.12B |
|
$147.25M |
|
$319.39M |
|
$2.44B |
|
$118.99M |
|
-- |
|
$236.09M |
|
$355.08M |
|
$2.08B |
|
$2.08B |
|
$2.08B |
|
84.84M |
|
| Cash Flow Statement Financials | |
$109.75M |
|
$-97.80M |
|
$305.93M |
|
$401.07M |
|
$718.94M |
|
$317.88M |
|
$19.41M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.81 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-27894.25% |
|
-27894.25% |
|
-- |
|
-22989.48% |
|
-23133.14% |
|
$109.03M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-5.59% |
|
-5.59% |
|
-4.78% |
|
|
Return on Investments |
-5.59% |
$24.56 |
|
$1.33 |
|
$1.34 |
|